A study of DTP3 for advanced myeloma
Cancer type:
Blood cancers
Myeloma
Status:
Results
Phase:
Phase 1/2
This study was for people whose myeloma had come back or treatment had stopped working.
More about this trial
There are a number of ways to treat myeloma. But sometimes the myeloma comes back after treatment or stops responding to it.
So doctors are looking at new treatments to help this group of people. In this study, they looked at DTP3.
DTP3 is a targeted cancer drug. It kills myeloma cells but doesn’t affect normal cells. This meant it might have fewer side effects.
The main aims of the study were to:
- find the best safe dose of DTP3
- learn more about the side effects
- find out what happened in the body
- find how well DTP3 might work
Summary of results
The study team found that DTP3 could be used to treat people with myeloma that had come back or when treatment had stopped working.
This study was open to people to join between 2016 and 2017.
These results were published in 2018.
About this study
The team looked at 3 different doses of DTP3.
Results
3 people took part in this study. Each person had a different dose of DTP3.
2 people had 1 cycle of treatment of DTP3 and 1 person had 3 cycles, each lasting 1 month. No one reported any side effects that might stop their treatment.
Doctors look at substances in the urine and blood (biomarkers 
) called free light chains and paraprotein. This helps to find out how well treatments might work for myeloma.
) called free light chains and paraprotein. This helps to find out how well treatments might work for myeloma. When the researchers looked at these they found that for 1 person these had decreased in the blood. This was in keeping with their myeloma which was not getting any worse.
This person’s free light chains and paraprotein stayed this way for 3 treatment cycles of DTP3 before their myeloma started to get worse again.
The team looked at blood test results and bone marrow test results to find what was happening in the body. They found that DTP3 triggered programmed cell death (apoptosis ) for myeloma cells but not for healthy cells. This meant it killed myeloma cells but didn’t affect healthy cells.
test results to find what was happening in the body. They found that DTP3 triggered programmed cell death () for myeloma cells but not for healthy cells. This meant it killed myeloma cells but didn’t affect healthy cells. Conclusion
The study team concluded that these initial results are encouraging. And they are planning to do larger clinical trials to find how well DTP3 might work for people with myeloma.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed ) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Professor Jane Apperley
Supported by
Imperial College London
Medical Research Council
NIHR Imperial Clinical Trial Facility
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
13796
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
